Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2003 Sep;58(9):784–789. doi: 10.1136/thorax.58.9.784

Screening for lung cancer: a systematic review and meta-analysis of controlled trials

R Manser 1, L Irving 1, G Byrnes 1, M Abramson 1, C Stone 1, D Campbell 1
PMCID: PMC1746815  PMID: 12947138

Abstract

Background: Lung cancer is a substantial public health problem in western countries. Previous studies have examined different screening strategies for lung cancer but there have been no published systematic reviews.

Methods: A systematic review of controlled trials was conducted to determine whether screening for lung cancer using regular sputum examinations or chest radiography or computed tomography (CT) reduces lung cancer mortality. The primary outcome was lung cancer mortality; secondary outcomes were lung cancer survival and all cause mortality.

Results: One non-randomised controlled trial and six randomised controlled trials with a total of 245 610 subjects were included in the review. In all studies the control group received some type of screening. More frequent screening with chest radiography was associated with an 11% relative increase in mortality from lung cancer compared with less frequent screening (RR 1.11, 95% CI 1.00 to 1.23). A non-statistically significant trend to reduced mortality from lung cancer was observed when screening with chest radiography and sputum cytological examination was compared with chest radiography alone (RR 0.88, 95% CI 0.74 to 1.03). Several of the included studies had potential methodological weaknesses. Controlled studies of spiral CT scanning have not been reported.

Conclusions: The current evidence does not support screening for lung cancer with chest radiography or sputum cytological examination. Frequent chest radiography might be harmful. Further methodologically rigorous trials are required before any new screening methods are introduced into clinical practice.

Full Text

The Full Text of this article is available as a PDF (115.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen B. L., Farrar W. B., Golden-Kreutz D., Kutz L. A., MacCallum R., Courtney M. E., Glaser R. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst. 1998 Jan 7;90(1):30–36. doi: 10.1093/jnci/90.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Black W. C. Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst. 2000 Aug 16;92(16):1280–1282. doi: 10.1093/jnci/92.16.1280. [DOI] [PubMed] [Google Scholar]
  3. Brett G. Z. Earlier diagnosis and survival in lung cancer. Br Med J. 1969 Nov 1;4(5678):260–262. doi: 10.1136/bmj.4.5678.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Faller H., Bülzebruck H., Drings P., Lang H. Coping, distress, and survival among patients with lung cancer. Arch Gen Psychiatry. 1999 Aug;56(8):756–762. doi: 10.1001/archpsyc.56.8.756. [DOI] [PubMed] [Google Scholar]
  5. Flehinger B. J., Melamed M. R. Current status of screening for lung cancer. Chest Surg Clin N Am. 1994 Feb;4(1):1–15. [PubMed] [Google Scholar]
  6. Fontana R. S., Sanderson D. R., Woolner L. B., Taylor W. F., Miller W. E., Muhm J. R., Bernatz P. E., Payne W. S., Pairolero P. C., Bergstralh E. J. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer. 1991 Feb 15;67(4 Suppl):1155–1164. doi: 10.1002/1097-0142(19910215)67:4+<1155::aid-cncr2820671509>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  7. Friedman G. D., Collen M. F., Fireman B. H. Multiphasic Health Checkup Evaluation: a 16-year follow-up. J Chronic Dis. 1986;39(6):453–463. doi: 10.1016/0021-9681(86)90112-8. [DOI] [PubMed] [Google Scholar]
  8. Gøtzsche P. C., Olsen O. Is screening for breast cancer with mammography justifiable? Lancet. 2000 Jan 8;355(9198):129–134. doi: 10.1016/S0140-6736(99)06065-1. [DOI] [PubMed] [Google Scholar]
  9. Henschke C. I., McCauley D. I., Yankelevitz D. F., Naidich D. P., McGuinness G., Miettinen O. S., Libby D. M., Pasmantier M. W., Koizumi J., Altorki N. K. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999 Jul 10;354(9173):99–105. doi: 10.1016/S0140-6736(99)06093-6. [DOI] [PubMed] [Google Scholar]
  10. Henschke C. I., Yankelevitz D. F. Screening for lung cancer. J Thorac Imaging. 2000 Jan;15(1):21–27. doi: 10.1097/00005382-200001000-00005. [DOI] [PubMed] [Google Scholar]
  11. Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J., Gavaghan D. J., McQuay H. J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4. [DOI] [PubMed] [Google Scholar]
  12. Janssen-Heijnen M. L., Coebergh J. W. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer. 2001 Feb-Mar;31(2-3):123–137. doi: 10.1016/s0169-5002(00)00197-5. [DOI] [PubMed] [Google Scholar]
  13. Kramer B. S., Gohagan J., Prorok P. C., Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer. 1993 Jan 15;71(2 Suppl):589–593. doi: 10.1002/cncr.2820710215. [DOI] [PubMed] [Google Scholar]
  14. Kubik A., Parkin D. M., Khlat M., Erban J., Polak J., Adamec M. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer. 1990 Jan 15;45(1):26–33. doi: 10.1002/ijc.2910450107. [DOI] [PubMed] [Google Scholar]
  15. Kubík A. K., Parkin D. M., Zatloukal P. Czech Study on Lung Cancer Screening: post-trial follow-up of lung cancer deaths up to year 15 since enrollment. Cancer. 2000 Dec 1;89(11 Suppl):2363–2368. doi: 10.1002/1097-0142(20001201)89:11+<2363::aid-cncr9>3.3.co;2-n. [DOI] [PubMed] [Google Scholar]
  16. Lardinois Didier, Weder Walter, Hany Thomas F., Kamel Ehab M., Korom Stephan, Seifert Burkhardt, von Schulthess Gustav K., Steinert Hans C. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003 Jun 19;348(25):2500–2507. doi: 10.1056/NEJMoa022136. [DOI] [PubMed] [Google Scholar]
  17. Marcus P. M., Bergstralh E. J., Fagerstrom R. M., Williams D. E., Fontana R., Taylor W. F., Prorok P. C. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst. 2000 Aug 16;92(16):1308–1316. doi: 10.1093/jnci/92.16.1308. [DOI] [PubMed] [Google Scholar]
  18. Marcus P. M., Prorok P. C. Reanalysis of the Mayo Lung Project data: the impact of confounding and effect modification. J Med Screen. 1999;6(1):47–49. doi: 10.1136/jms.6.1.47. [DOI] [PubMed] [Google Scholar]
  19. Melamed M. R., Flehinger B. J., Zaman M. B., Heelan R. T., Perchick W. A., Martini N. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest. 1984 Jul;86(1):44–53. doi: 10.1378/chest.86.1.44. [DOI] [PubMed] [Google Scholar]
  20. Moher D., Schulz K. F., Altman D. G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001 Apr 14;357(9263):1191–1194. [PubMed] [Google Scholar]
  21. Mossman K. L. Analysis of risk in computerized tomography and other diagnostic radiology procedures. Comput Radiol. 1982 Sep-Oct;6(5):251–256. doi: 10.1016/0730-4862(82)90109-3. [DOI] [PubMed] [Google Scholar]
  22. Mulshine J. L., De Luca L. M., Dedrick R. L., Tockman M. S., Webster R., Placke M. E. Considerations in developing successful, population-based molecular screening and prevention of lung cancer. Cancer. 2000 Dec 1;89(11 Suppl):2465–2467. doi: 10.1002/1097-0142(20001201)89:11+<2465::aid-cncr24>3.3.co;2-y. [DOI] [PubMed] [Google Scholar]
  23. Parkin D. M., Pisani P. Screening for lung cancer. Cancer Treat Res. 1996;86:121–128. doi: 10.1007/978-1-4613-1265-9_9. [DOI] [PubMed] [Google Scholar]
  24. Parmar M. K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998 Dec 30;17(24):2815–2834. doi: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  25. Patz E. F., Jr, Goodman P. C., Bepler G. Screening for lung cancer. N Engl J Med. 2000 Nov 30;343(22):1627–1633. doi: 10.1056/NEJM200011303432208. [DOI] [PubMed] [Google Scholar]
  26. Ries L. A. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol. 1994 Jan-Feb;10(1):21–30. doi: 10.1002/ssu.2980100106. [DOI] [PubMed] [Google Scholar]
  27. Schulz K. F., Chalmers I., Hayes R. J., Altman D. G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995 Feb 1;273(5):408–412. doi: 10.1001/jama.273.5.408. [DOI] [PubMed] [Google Scholar]
  28. Sugarbaker D. J., Strauss G. M. Extent of surgery and survival in early lung carcinoma: implications for overdiagnosis in stage IA nonsmall cell lung carcinoma. Cancer. 2000 Dec 1;89(11 Suppl):2432–2437. doi: 10.1002/1097-0142(20001201)89:11+<2432::aid-cncr17>3.3.co;2-1. [DOI] [PubMed] [Google Scholar]
  29. Wilde J. A 10 year follow-up of semi-annual screening for early detection of lung cancer in the Erfurt County, GDR. Eur Respir J. 1989 Jul;2(7):656–662. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES